- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.03. | Citizens bekräftigt Rating für Acrivon nach Fortschritten bei Studie zu Endometriumkrebs | 11 | Investing.com Deutsch | ||
| 24.03. | Citizens reiterates Acrivon Therapeutics stock rating on endometrial cancer trial progress | 3 | Investing.com | ||
| 19.03. | Oppenheimer reiterates Acrivon stock rating on endometrial cancer focus | 8 | Investing.com | ||
| 19.03. | Acrivon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.03. | Acrivon Therapeutics GAAP EPS of -$0.49 misses by $0.01 | 3 | Seeking Alpha | ||
| 19.03. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | 235 | GlobeNewswire (Europe) | Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) Late-breaking oral presentation... ► Artikel lesen | |
| 19.03. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | Acrivon Therapeutics, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| ACRIVON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.03. | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint ... | 5 | GlobeNewswire (USA) | ||
| 02.03. | Jefferies reiterates Acrivon Therapeutics stock rating on trial data | 17 | Investing.com | ||
| 27.02. | Acrivon präsentiert auf ESGO-Kongress neue Daten zu Krebsmedikament ACR-368 | 10 | Investing.com Deutsch | ||
| 27.02. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.01. | Acrivon to present ACR-368 endometrial cancer data at ESGO congress | 17 | Investing.com | ||
| 23.01. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress | 10 | GlobeNewswire (USA) | ||
| 09.01. | Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data | 11 | Investing.com | ||
| 08.01. | Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data | 4 | RTTNews | ||
| 08.01. | Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls | 11 | Benzinga.com | ||
| 08.01. | Acrivon reports 52% response rate in serous endometrial cancer trial | 3 | Investing.com | ||
| 08.01. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.01. | Acrivon to provide clinical updates on cancer drug candidates | 2 | Investing.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| MODERNA | 43,330 | -0,30 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| PAION | 0,051 | -19,84 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| BIOGEN | 147,04 | -0,28 % | Biogen to acquire Apellis in $5.6bn deal | ||
| NANOREPRO | 1,455 | +2,83 % | Aktien KW 14 Trump spielt mit den Märkten - Kriegs-Ende oder nicht. News. Mutares. The Platform Group. Fortec. Norma Group. SUSS MicroTec. Pyramid. Nordex. NanoRepro. SFC Energy. 123fahrschule. Masterflex | Aktien - Immer noch Bomben auf den Iran. Trotz ansteigender Kritik und steigenden Preisen für die US-Wähler, Trump bleibt ratlos im Kampf. Am Mittwoch hofften alle auf die "Rede an die Nation". Am Ende... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| OCUGEN | 1,524 | +1,74 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,917 | +0,94 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| MAINZ BIOMED | 0,443 | -6,24 % | Mainz Biomed BV: EPS übertrifft Schätzungen um 1,11 $ - Umsatz schlechter als erwartet | ||
| VIKING THERAPEUTICS | 28,950 | -0,86 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| INFLARX | 0,841 | -1,87 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
| INTELLIA THERAPEUTICS | 11,400 | -1,04 % | Intellia Therapeutics, Inc. - 8-K, Current Report |
ACRIVON THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,94 % bei einem Aktienkurs von 1,580 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACRIVON THERAPEUTICS INC finden Sie auf Wallstreet Online.